Valuation: Veru Inc.

Market Cap 43.05M 37.86M 35.81M 32.48M 60.99M 4.13B 61.34M 429M 166M 2.11B 162M 158M 6.78B P/E 2026 *
-2.9x
P/E 2027 * -2.76x
Enterprise Value 43.05M 37.86M 35.81M 32.48M 60.99M 4.13B 61.34M 429M 166M 2.11B 162M 158M 6.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week+1.20%
Current month-9.64%
1 month-9.64%
3 months-18.91%
6 months+18.78%
Current year+18.22%
1 week 2.42
Extreme 2.4199
2.57
1 month 2.29
Extreme 2.29
2.85
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Buy

Chief Technology Officer

1,800 0.0112%
04/05/26 Free

Director

160,000 0.9969%
04/05/26 Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%+1.20%-31.62%-64.81% 43.05M
-0.70%-4.35%+56.10%+86.42% 71.81B
+0.09%-1.15%+38.35%+83.59% 60.06B
+0.19%+0.94%+36.97%+21.32% 27.93B
-2.39%-4.49%-18.53%+357.03% 25.7B
-1.34%-2.83%-0.08%-9.78% 24.89B
+0.65%+1.67%+26.47%-7.62% 20.92B
+3.46%+3.91%+158.90%+337.81% 15.04B
-0.87%-0.64%+42.41%+164.42% 14.46B
+3.91%-4.56%-2.71%+506.41% 13.87B
Average +0.19%-0.48%+30.63%+147.48% 27.47B
Weighted average by Cap. -0.10%-1.74%+37.87%+127.67%

Financials

2026 *2027 *
Net sales - -
Net income -23.3M -20.49M -19.38M -17.58M -33.01M -2.24B -33.2M -232M -89.61M -1.14B -87.48M -85.58M -3.67B -36.6M -32.19M -30.44M -27.61M -51.85M -3.51B -52.15M -364M -141M -1.79B -137M -134M -5.76B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
29/09/26 $2.530 +0.20% 4,670
28/09/26 $2.525 -0.59% 101,367
25/09/26 $2.540 +1.20% 116,069
24/09/26 $2.510 +2.03% 87,408
23/09/26 $2.460 -1.60% 94,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.525USD
Average target price
24.50USD
Spread / Average Target
+870.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock